Incruse Ellipta Coupons & Prices

Incruse Ellipta (umeclidinium) is a once-daily inhaled maintenance medicine for chronic obstructive pulmonary disease (COPD), and if you're comparing an Incruse Ellipta coupon against the manufacturer's savings card, it helps to know how each one actually works before you fill your prescription — enter your ZIP above to see today's price at nearby pharmacies.

What Is Incruse Ellipta and How Does It Work?

Incruse Ellipta delivers umeclidinium (umeclidinium bromide), a long-acting muscarinic antagonist (LAMA), as a dry inhalation powder through the Ellipta device. It's approved for once-daily maintenance treatment of airflow obstruction in adults with COPD, including chronic bronchitis and/or emphysema. Incruse Ellipta is not approved or studied for asthma.

The dose is one inhalation (62.5 mcg) once a day, at the same time each day. It is strictly a maintenance medicine — it is not for rescue use during a sudden flare-up, so patients on Incruse Ellipta still need a separate short-acting bronchodilator on hand for acute symptoms.

Manufacturer Savings Card vs. an Rx.com Cash Coupon

Incruse Ellipta does not currently have a generic equivalent, so brand-name pricing is what most patients are working with. GSK, the manufacturer, offers its own savings card program for Incruse Ellipta (available through GSK's official patient-support site); like most manufacturer copay cards, it's generally limited to patients with commercial insurance, and the terms, eligibility, and any coverage caps can change, so check the current details directly with GSK before assuming it applies to you.

An Rx.com cash coupon works differently: it isn't tied to your insurance status at all, so it can be useful if you're uninsured, on Medicare (manufacturer cards typically exclude government insurance), or if the pharmacy tells you the manufacturer card was declined at checkout. Some patients also compare the two and use whichever gives the better price at their specific pharmacy that day.

Incruse Ellipta vs. Anoro Ellipta and Other Ellipta Inhalers

Incruse Ellipta contains one active ingredient, umeclidinium, a LAMA bronchodilator alone. Anoro Ellipta combines that same umeclidinium with a second bronchodilator (a long-acting beta-agonist), so it's a two-in-one combination inhaler for patients whose COPD isn't controlled on a single bronchodilator. Trelegy Ellipta goes a step further as a triple-combination inhaler (adding an inhaled corticosteroid), while Breo Ellipta pairs an inhaled corticosteroid with a long-acting beta-agonist rather than a LAMA.

Outside the Ellipta device family, Spiriva (tiotropium) is another long-acting muscarinic antagonist used for COPD maintenance, delivered through a different inhaler device. Which of these is right for a given patient depends on how well their COPD is controlled on a single medicine versus a combination — that's a decision for your prescriber, not something to change on your own.

Safety Information for Incruse Ellipta

Incruse Ellipta does not carry an FDA boxed warning. Because it's a maintenance-only medicine, the label warns that it should never be used to treat sudden breathing symptoms — keep a rescue inhaler available separately. The label also warns that Incruse Ellipta can, in rare cases, cause paradoxical bronchospasm (call your provider if breathing suddenly worsens after a dose), and that its anticholinergic effect can worsen narrow-angle glaucoma or cause urinary retention, particularly in men with an enlarged prostate or bladder-neck obstruction. Immediate hypersensitivity reactions have been reported, and combining Incruse Ellipta with other anticholinergic medicines is not recommended.

• Common side effects: nasopharyngitis, upper respiratory tract infection, cough, joint pain (arthralgia), and back pain.

This is a summary, not medical advice — talk to your doctor or pharmacist about whether Incruse Ellipta is right for you and about any other medicines or eye or urinary conditions you have.